KRAS and colorectal carcinoma: Two DNA methylation biomarker panels are FDA approved for early detection of CRC: (1) SEPT9 in tissue and blood plasma, marketed as Epi proColon, and (2) BMP3 and NDRG4 DNA methylation with KRAS mutation screening in stool, marketed as Cologuard.